Sarepta Therapeutics Announces Strong Preliminary Results for 2023
Sarepta Therapeutics, Inc. has reported a significant uptick in share value as of January 8, following the release of its strong preliminary results for the fourth quarter and the full year of 2023. The company, a key player in the biopharmaceutical industry, has a commercial portfolio that primarily targets Duchenne muscular dystrophy (DMD) with three approved RNA-based PMO therapies—Exondys 51, Vyondys 53, and Amondys 45. Marking a milestone in the treatment of DMD, the company also heralded the approval of its gene therapy, Elevidys (delandistrogene moxeparvovec-rokl).
The preliminary total net product revenues for the year are anticipated to reach approximately $1.14 billion. The RNA-based PMO therapies are expected to account for roughly $945 million of the annual revenue, surpassing the company’s previous projections. Elevidys, the newly approved gene therapy, is projected to contribute net product sales of about $200.4 million for the year, a figure that notably exceeds initial expectations. The company’s preliminary cash, cash equivalents, and investments as of December 31, 2023, are estimated to be close to $1.7 billion.
In June 2023, the FDA granted accelerated approval to Elevidys for the treatment of ambulatory pediatric patients aged four to five years with DMD, distinguishing it as the first approved gene therapy for this condition. The company has taken further steps by submitting a supplement to the biologics license application (BLA) for Elevidys, seeking full approval to treat all DMD patients, irrespective of their age and ambulation status, and has requested a priority review for this submission.
The development and commercialization of Elevidys are the result of a collaborative effort between Sarepta and Roche. This partnership, which began in 2019, provides Roche with exclusive rights to launch and commercialize Elevidys in territories outside the United States. The company benefits from collaboration revenues through this licensing agreement with Roche.
Sarepta’s trajectory in the healthcare sector is highlighted by its strong performance and the transformative potential of its therapies for individuals affected by DMD. The company’s commitment to advancing treatment options for this challenging condition is reflected in its robust product pipeline and the strategic partnerships it has cultivated.
The preliminary results for 2023 underscore Sarepta Therapeutics’ dedication to innovation and its focus on meeting the unmet needs of patients with Duchenne muscular dystrophy. The company’s portfolio, including RNA-based PMO therapies and the pioneering gene therapy Elevidys, has been instrumental in its robust performance. Sarepta’s efforts to broaden the treatment indications for Elevidys underscore its ongoing commitment to improving patient outcomes. As the company forges ahead, its contributions to medical science and the well-being of patients with DMD continue to be of critical significance.
Source link
